Biocryst Pharmaceuticals (BCRX) Other financing activities (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Other financing activities came in at $19.5 million in Q1 2026, up 715.02% YoY from $2.4 million in Q1 2025, and up 2864.84% on a QoQ basis from $657000.0 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Other financing activities (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Other financing activities data on file, last reported at $19.5 million in Q1 2026.
- Quarterly Other financing activities rose 715.02% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (up 530.97% YoY) and the FY2025 annual result came in at $9.1 million, up 164.66% from the prior year.
- Other financing activities climbed to $19.5 million in Q1 2026, from $657000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $19.5 million in Q1 2026 to a low of -$586000.0 in Q4 2024.
- A 5-year average of $3.2 million and a median of $2.1 million in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities plunged 1602.56% — and 2025, when it jumped 1195.83%.
- Tracing BCRX's Other financing activities over 5 years: stood at $4.0 million in 2022, then sank by 99.03% to $39000.0 in 2023, then sank by 1602.56% to -$586000.0 in 2024, then jumped by 212.12% to $657000.0 in 2025, then soared by 2864.84% to $19.5 million in 2026.
- The last three Other financing activities figures came in at $19.5 million (Q1 2026), $657000.0 (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.10 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.20 Mn |
| Jun 30, 2026 | 6.20 Mn |
| Mar 31, 2026 | 19.48 Mn |
| Mar 31, 2026 | 19.48 Mn |
| Dec 31, 2025 | 657,000.00 |
| Dec 31, 2025 | 657,000.00 |
| Sep 30, 2025 | 2.65 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | 3.42 Mn |
| Jun 30, 2025 | 3.42 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Dec 31, 2024 | -586,000.00 |
| Dec 31, 2024 | -586,000.00 |
| Sep 30, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 264,000.00 |
| Jun 30, 2024 | 264,000.00 |
| Mar 31, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.68 Mn |